We are live on ! Find out more
SLXN icon

Silexion Therapeutics

4 hedge funds and large institutions have $17.3K invested in Silexion Therapeutics in 2025 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

3.5% less ownership

Funds ownership: 3.66% → 0.16% (-3.5%)

43% less funds holding

Funds holding: 7 → 4 (-3)

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

87% less capital inflows, than outflows

Capital inflows: $27.9K | Capital outflows: $212K

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-3
Holders Change %
-42.86%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
–
Reduced
2
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

SLXN Hedge Fund Activity: Q3 2025 in Review

4 of the 7,665 institutional investors tracked by Wall St. Rank reported a position in Silexion Therapeutics (SLXN) for Q3 2025, worth a combined $17.3K — down 93% from $258K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of SLXN and 2 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Montag & Associates, opening a new position worth an estimated $25.9K. The largest seller was Wildcat Capital Management, exiting entirely with an estimated $91.9K sold.

  • 4 institutional investors held Silexion Therapeutics (SLXN) as of Q3 2025, down from 7 in Q2 2025.
  • Funds reported $17.3K of Silexion Therapeutics stock for Q3 2025, down 93% quarter-over-quarter.
  • 2 funds opened new Silexion Therapeutics positions in Q3 2025 and 5 closed out, a net change of -3 holders.
  • The largest Silexion Therapeutics buyer in Q3 2025 was Montag & Associates, an estimated $25.9K added.
  • The largest Silexion Therapeutics seller in Q3 2025 was Wildcat Capital Management, an estimated $91.9K sold.

Based on aggregated 13F filings for Q3 2025.